1. Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma
- Author
-
Benavides-Serrato, Angelica, Saunders, Jacquelyn T, Holmes, Brent, Nishimura, Robert N, Lichtenstein, Alan, and Gera, Joseph
- Subjects
Medicinal and Biomolecular Chemistry ,Chemical Sciences ,Rare Diseases ,Brain Disorders ,Orphan Drug ,Cancer ,Brain Cancer ,Neurosciences ,5.1 Pharmaceuticals ,Animals ,Antineoplastic Agents ,Apoptosis ,Cell Line ,Tumor ,Cell Movement ,Cell Proliferation ,Drug Repositioning ,Drug Resistance ,Neoplasm ,Drug Synergism ,Female ,Glioblastoma ,Heterogeneous Nuclear Ribonucleoprotein A1 ,Humans ,Internal Ribosome Entry Sites ,Mice ,Mice ,SCID ,Molecular Docking Simulation ,Protein Biosynthesis ,Riluzole ,TOR Serine-Threonine Kinases ,riluzole ,hnRNP A1 ,ITAF ,mTOR ,drug resistance ,glioblastoma ,Other Chemical Sciences ,Genetics ,Other Biological Sciences ,Chemical Physics ,Biochemistry and cell biology ,Microbiology ,Medicinal and biomolecular chemistry - Abstract
Internal ribosome entry site (IRES)-mediated protein synthesis has been demonstrated to play an important role in resistance to mechanistic target of rapamycin (mTOR) targeted therapies. Previously, we have demonstrated that the IRES trans-acting factor (ITAF), hnRNP A1 is required to promote IRES activity and small molecule inhibitors which bind specifically to this ITAF and curtail IRES activity, leading to mTOR inhibitor sensitivity. Here we report the identification of riluzole (Rilutek®), an FDA-approved drug for amyotrophic lateral sclerosis (ALS), via an in silico docking analysis of FDA-approved compounds, as an inhibitor of hnRNP A1. In a riluzole-bead coupled binding assay and in surface plasmon resonance imaging analyses, riluzole was found to directly bind to hnRNP A1 and inhibited IRES activity via effects on ITAF/RNA-binding. Riluzole also demonstrated synergistic anti-glioblastoma (GBM) affects with mTOR inhibitors in vitro and in GBM xenografts in mice. These data suggest that repurposing riluzole, used in conjunction with mTOR inhibitors, may serve as an effective therapeutic option in glioblastoma.
- Published
- 2020